ORCID Profile
0000-0001-5318-1675
Current Organisations
CSIRO
,
UNSW Graduate Research School
,
CSIRO Health and Biosecurity
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Springer Science and Business Media LLC
Date: 05-2017
DOI: 10.1038/545S21A
Publisher: American Chemical Society (ACS)
Date: 07-12-2021
DOI: 10.1021/ACSSENSORS.1C01973
Abstract: The spread of antimicrobial resistance (AMR) is a rapidly growing threat to humankind on both regional and global scales. As countries worldwide prepare to embrace a One Health approach to AMR management, which is one that recognizes the interconnectivity between human, animal, and environmental health, increasing attention is being paid to identifying and monitoring key contributing factors and critical control points. Presently, AMR sensing technologies have significantly progressed phenotypic antimicrobial susceptibility testing (AST) and genotypic antimicrobial resistance gene (ARG) detection in human healthcare. For effective AMR management, an evolution of innovative sensing technologies is needed for tackling the unique challenges of interconnected AMR across various and different health domains. This review comprehensively discusses the modern state-of-play for innovative commercial and emerging AMR sensing technologies, including sequencing, microfluidic, and miniaturized point-of-need platforms. With a unique view toward the future of One Health, we also provide our perspectives and outlook on the constantly changing landscape of AMR sensing technologies beyond the human health domain.
Publisher: Springer Science and Business Media LLC
Date: 05-2011
DOI: 10.1038/NM0511-521A
Publisher: Springer Science and Business Media LLC
Date: 05-2011
DOI: 10.1038/NM0511-521B
Publisher: Springer Science and Business Media LLC
Date: 07-2010
DOI: 10.1038/NM0710-730
Publisher: Elsevier BV
Date: 2002
DOI: 10.1016/S0166-2236(00)02039-7
Abstract: The Joint International and American Neurochemistry Society Meeting was held, in collaboration with SAN (Sociedad Argentina de Neuroquímica), in Buenos Aires, Argentina from 26-31 August 2001.
Publisher: Springer Science and Business Media LLC
Date: 05-2016
DOI: 10.1038/533S116A
Publisher: Springer Science and Business Media LLC
Date: 03-2011
DOI: 10.1038/NM0311-267
Publisher: Springer Science and Business Media LLC
Date: 10-08-2017
DOI: 10.1038/548S9A
Publisher: Elsevier BV
Date: 03-2004
Publisher: Springer Science and Business Media LLC
Date: 05-2006
DOI: 10.1007/S11046-006-0240-5
Abstract: Dothistromin is a polyketide toxin, produced by a fungal forest pathogen, with structural similarity to the aflatoxin precursor versicolorin B. Biochemical and genetic studies suggested that there are common steps in the biosynthetic pathways for these metabolites and showed similarities between some of the genes. A polyketide synthase gene (pksA) was isolated from dothistromin-producing Dothistroma septosporum by hybridization with an aflatoxin ortholog from Aspergillus parasiticus. Inactivation of this gene in D. septosporum resulted in mutants that could not produce dothistromin but that could convert exogenous aflatoxin precursors, including norsolorinic acid, into dothistromin. The mutants also had reduced asexual sporulation compared to the wild type. So far four other genes are known to be clustered immediately alongside pksA. Three of these (cypA, moxA, avfA) are predicted to be orthologs of aflatoxin biosynthetic genes. The other gene (epoA), located between avfA and moxA, is predicted to encode an epoxide hydrolase, for which there is no homolog in either the aflatoxin or sterigmatocystin gene clusters. The pksA gene is located on a small chromosome of approximately 1.3 Mb in size, along with the dothistromin ketoreductase (dotA) gene.
Publisher: Springer Science and Business Media LLC
Date: 07-2014
DOI: 10.1038/511S72A
Publisher: Wiley
Date: 16-08-2004
Publisher: CSIRO Publishing
Date: 2019
DOI: 10.1071/MA19021
Abstract: Antimicrobial resistance (AMR) threatens modern medicine as we know it. AMR infections may ultimately be untreatable and routine surgeries will become inherently risky1. By 2050 more people may die of drug-resistant infections (DRIs) every year than of cancer, which equates to more than 10 million annual deaths globally2 and the World Bank has estimated that AMR could cost the global economy $1 trillion every year after 2030. DRIs also lead to an increase in the length of hospital stays, the use of more toxic or costly antibiotics and an increased likelihood of death3. BRIC nations (Brazil, Russia, India, China) and socio-economically challenged countries and people who already have higher rates of infectious diseases will feel the greatest impact2. Indeed, AMR has been likened to the 2008 global financial crisis on an annual repeat cycle. That is because the effects of AMR are not just confined to the human medical sector. The veterinary sector is also reliant on the availability of antimicrobials to treat infectious diseases in companion and food-producing animals.
Publisher: Springer Science and Business Media LLC
Date: 12-2014
DOI: 10.1038/516S8A
Location: Australia
No related grants have been discovered for Branwen Morgan.